Form 4: OptiNose Director's Stock Options Canceled Following Merger with Paratek Pharmaceuticals

Director John Fletcher's stock options in OptiNose were canceled or converted to contingent value rights (CVRs) following the merger with Paratek Pharmaceuticals on May 21, 2025.

Summary

• On May 21, 2025, OptiNose merged with Paratek Pharmaceuticals, with OptiNose becoming a wholly-owned subsidiary of Paratek.
• As a result of the merger, each outstanding share of OptiNose common stock was converted into the right to receive $9.00 in cash and one contingent value right (CVR).
• Director John Fletcher's stock options were affected by the merger.
• Options with an exercise price greater than $14.00 were canceled for no consideration.
• Options with an exercise price between $9.00 and $14.00 were canceled and converted into the right to receive one CVR, with the amount payable reduced by the difference between the exercise price and $9.00.
• Options with an exercise price less than $9.00 were converted into the right to receive cash equal to the difference between $9.00 and the exercise price.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting the facts of the transaction and its impact on the reporting person's holdings. The merger itself could be viewed as positive or negative depending on individual shareholder perspectives.

Negatives

• John Fletcher's stock options with exercise prices exceeding $14.00 were canceled without compensation as a result of the merger.

Future Outlook

The document outlines the immediate impact of the merger on the reporting person's stock options and the potential for future payments based on the CVR agreement.

Industry Context

This announcement reflects a common outcome in mergers and acquisitions, where outstanding equity awards are addressed through cash payouts, CVRs, or cancellation, depending on the terms of the merger agreement and the specific characteristics of the awards.

Comparison to Industry Standards

• The treatment of stock options in this merger is consistent with standard M&A practice, where unvested or out-of-the-money options are often canceled or converted into alternative forms of consideration.
• The use of CVRs is a common mechanism to bridge valuation gaps between the acquirer and target company, providing potential upside to former shareholders based on the achievement of specific milestones.
• Similar to the acquisition of Immunomedics by Gilead, where CVRs were used, the OptiNose deal uses CVRs to provide additional value contingent on future performance.

Stakeholder Impact

• Shareholders received $9.00 in cash and one CVR per share.
• Option holders received cash or CVRs depending on the exercise price of their options.
• Employees of OptiNose are now employees of a wholly-owned subsidiary of Paratek Pharmaceuticals.

Key Dates

Keywords

Merger, OptiNose, Paratek Pharmaceuticals, Stock Options, Contingent Value Rights, CVR, Director, Form 4, Beneficial Ownership